Table 1.
Patient characteristics before, 1 mo, and 6 mo after RYGB
| Time Point |
||||
|---|---|---|---|---|
| Outcome | Group | Presurgery | 1 Mo Post | 6 Mo Post |
| BMI | CON | 23.3 ± 0.9 | ||
| Non-T2D | 49.4 ± 1.9 | 44.3 ± 1.9* | 36.0 ± 1.8*† | |
| T2D | 47.0 ± 2.2 | 41.7 ± 2.2* | 34.5 ± 2.0*† | |
| HbA1C, % | CON | 5.6 ± 0.1 | ||
| Non-T2D | 5.9 ± 0.2 | 5.5 ± 0.2* | 5.4 ± 0.2* | |
| T2D | 7.1 ± 0.2# | 6.1 ± 0.2* | 5.9 ± 0.2* | |
| HOMA-IR | CON | 0.6 ± 0.1 | ||
| Non-T2D | 3.0 ± 0.3 | 1.9 ± 0.3* | 1.0 ± 0.3*† | |
| T2D | 3.8 ± 0.3 | 1.9 ± 0.3* | 1.3 ± 0.3*† | |
Data are means ± SE. BMI, body mass index; CON, control; HOMA-IR, homeostatic model assessment of insulin resistance; RYGB, Roux-en-Y gastric bypass surgery; T2D, type 2 diabetes.
*
P ≤ 0.05 compared with presurgery value;
†
P < 0.05 compared with 1-mo value;
#
P ≤ 0.05 compared with non-T2D at the same time point.